24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial

The Lancet Neurology

Volumn 16, Issue 12, 2017, Pages 965-975

  Soininen, Hilkka ^a,b   Solomon, Alina ^a,c,d   Visser, Pieter Jelle ^e,f   Hendrix, Suzanne B ^g   Blennow, Kaj ^h,i   Kivipelto, Miia ^a,c,d   Hartmann, Tobias ^j   Hallikainen, Ilona ^k   Hallikainen, Merja ^k   Helisalmi, Seppo ^k   Lappalainen, Tarja ^k   Liu, Yawu ^k   Paajanen, Teemu ^k   Wahlund, Lars Olof ^k   Freund Levi, Yvonne ^k   Andreasen, Niels ^k   Hagman, Göran ^k   Lindblom, Stina ^k   Fassbender, Klaus ^k   Riemenschneider, Matthias ^k   Grimm, Marcus OW ^k   Klees Rollmann, Aline ^k   Luley, Maxine ^k   Lyros, Epameinondas ^k   Schomburg, Robert ^k   Kennel, Jennifer ^k   Ramelli, Daniela ^k   Frölich, Lutz ^k   Hausner, Lucrezia ^k   Laske, Christoph ^k   Leyhe, Thomas ^k   Mychajliw, Christian ^k   Koehler, Niklas ^k   Schiekofer, Stephan ^k   Klünemann, Hans ^k   Schröder, Johannes ^k   Lütjohann, Dieter ^k   Scheltens, Philip ^k   van Rossum, Ineke ^k   Scheltens, Nienke ^k   Bertens, Daniela ^k   ten Kate, Mara ^k   Barkhof, Frederik ^k   Henselmans, Johanna ML ^k   Roks, Gerwin ^k   van Hees, Anneke MJ ^k   Ellison, Noel ^k   more..

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Pentara Corporation   (United States)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j SAARLAND UNIVERSITY   (Germany)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; FLUORODEOXYGLUCOSE F 18; GALANTAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMANTINE; PROTEIN CONCENTRATE PLUS CARBOHYDRATES PLUS LIPIDS PLUS MINERALS PLUS VITAMINS; RIVASTIGMINE; DOCOSAHEXAENOIC ACID; FORTASYN CONNECT; ICOSAPENTAENOIC ACID; PHOSPHOLIPID;

ADULT; AGED; ALZHEIMER DISEASE; ARTHRALGIA; ARTICLE; BACKACHE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COUGHING; CYSTITIS; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DSM-IV; FEMALE; GERMANY; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; NORMOTENSIVE HYDROCEPHALUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SAMPLE SIZE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO; CLINICAL TRIAL; DIET THERAPY; MIDDLE AGED; OUTCOME ASSESSMENT; PRODROMAL SYMPTOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHOLIPIDS; PRODROMAL SYMPTOMS;

EID: 85033663926     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30332-0     Document Type: Article

References (38)

1. Aisen, PS, Andrieu, S, Sampaio, C, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76 (2011), 280–286.
2. Scheltens, P, Blennow, K, Breteler, MM, et al. Alzheimer's disease. Lancet 388 (2016), 505–517.
3. Dubois, B, Feldman, HH, Jacova, C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007), 734–746.
4. Dubois, B, Feldman, HH, Jacova, C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
5. Albert, MS, DeKosky, ST, Dickson, D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 270–279.
6. Ngandu, T, Lehtisalo, J, Solomon, A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385 (2015), 2255–2263.
7. Andrieu, S, Guyonnet, S, Coley, N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 16 (2017), 377–389.
8. Scarmeas, N, Stern, Y, Mayeux, R, Manly, JJ, Schupf, N, Luchsinger, JA, Mediterranean diet and mild cognitive impairment. Arch Neurol 66 (2009), 216–225.
9. Smith, AD, Smith, SM, de Jager, CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One, 5, 2010, e12244.
10. van Wijk, N, Broersen, LM, de Wilde, MC, et al. Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. J Alzheimers Dis 38 (2014), 459–479.
11. de Wilde, MC, Hogyes, E, Kiliaan, AJ, Farkas, T, Luiten, PG, Farkas, E, Dietary fatty acids alter blood pressure, behavior and brain membrane composition of hypertensive rats. Brain Res 988 (2003), 9–19.
12. Wurtman, RJ, Ulus, IH, Cansev, M, Watkins, CJ, Wang, L, Marzloff, G, Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 1088 (2006), 83–92.
13. de Wilde, MC, Penke, B, van der Beek, EM, Kuipers, AA, Kamphuis, PJ, Broersen, LM, Neuroprotective effects of a specific multi-nutrient intervention against Abeta42-induced toxicity in rats. J Alzheimers Dis 27 (2011), 327–339.
14. Savelkoul, PJM, Merkes, MMP, Janíèková, H, et al. A specific multi-nutrient formulation enhances M1 muscarinic acetylcholine receptor responses in vitro. J Neurochem 120 (2012), 631–640.
15. Broersen, LM, Kuipers, AA, Balvers, M, et al. A specific multi-nutrient diet reduces alzheimer-like pathology in young adult AbetaPPswe/PS1dE9 mice. J Alzheimers Dis 33 (2013), 177–190.
16. Koivisto, H, Grimm, MO, Rothhaar, TL, et al. Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer's disease independent of brain amyloid deposition. J Nutr Biochem 25 (2014), 157–169.
17. Zerbi, V, Jansen, D, Wiesmann, M, et al. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease. Neurobiol Aging 35 (2014), 600–613.
18. Holguin, S, Martinez, J, Chow, C, Wurtman, R, Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J 22 (2008), 3938–3946.
19. Jansen, D, Zerbi, V, Arnoldussen, IA, et al. Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in AbetaPPswe-PS1dE9 mice. PLoS One, 8, 2013, e75393.
20. Cansev, M, van Wijk, N, Turkyilmaz, M, Orhan, F, Sijben, JWC, Broersen, LM, A specific multi-nutrient enriched diet enhances hippocampal cholinergic transmission in aged rats. Neurobiol Aging 36 (2015), 344–351.
21. Janickova, H, Rudajev, V, Dolejsi, E, et al. Lipid-based diets improve muscarinic neurotransmission in the hippocampus of transgenic APPswe/PS1dE9 Mice. Curr Alzheimer Res 12 (2015), 923–931.
22. de Wilde, MC, Vellas, B, Girault, E, Yavuz, AC, Sijben, JW, Lower brain and blood nutrient status in Alzheimer's disease: results from meta-analyses. Alzheimers Dement 3 (2017), 416–431.
23. Scheltens, P, Kamphuis, PJ, verhey, FRJ, et al. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement 6 (2010), 1–10.e1.
24. Scheltens, P, Twisk, JW, Blesa, R, et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis 31 (2012), 225–236.
25. de Waal, H, Stam, CJ, Lansbergen, MM, et al. The effect of Souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. PLoS One, 9, 2014, e86558.
26. Shah, RC, Kamphuis, PJ, Leurgans, S, et al. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimers Res Ther, 5, 2013, 59.
27. Olde Rikkert, MG, Verhey, FR, Blesa, R, et al. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. J Alzheimers Dis 44 (2015), 471–480.
28. Cummings, J, Scheltens, P, McKeith, I, et al. Effect size analyses of Souvenaid in patients with Alzheimer's disease. J Alzheimers Dis 55 (2017), 1131–1139.
29. Harrison, J, Minassian, SL, Jenkins, L, Black, RS, Koller, M, Grundman, M, A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64 (2007), 1323–1329.
30. Hamel, R, Kohler, S, Sistermans, N, et al. The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. Psychol Med 45 (2015), 1509–1519.
31. Ellis, KA, Szoeke, C, Bush, AI, et al. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Int Psychogeriatr 26 (2014), 543–554.
32. Kamphuis, PJ, Verhey, FR, Olde Rikkert, MG, Twisk, JW, Swinkels, SH, Scheltens, P, Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 15 (2011), 720–724.
33. Vellas, B, Bateman, R, Blennow, K, et al. Endpoints for pre-dementia AD trials: a report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis 2 (2015), 128–135.
34. Vellas, B, Andrieu, S, Sampaio, C, Coley, N, Wilcock, G, Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 7 (2008), 436–450.
35. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry, Alzheimer's Disease: developing drugs for the treatment of early stage disease, draft guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf, 2013 (accessed Dec 20, 2016).
36. European Medicines Agency. Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500200830.pdf, Jan 28, 2016 (accessed Dec 20, 2016).
37. Vos, SJ, Verhey, F, Frolich, L, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 138 (2015), 1327–1338.
38. Coric, V, Salloway, S, van Dyck, CH, et al. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol 72 (2015), 1324–1333.